Author: Solid Biosciences Inc.

Posted Date:

May 8, 2026

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences Inc.

May 8, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc.

May 8, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Inc.

May 7, 2026
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences Inc.

May 7, 2026
Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc.

May 5, 2026
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Inc.

May 3, 2026
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

Solid Biosciences Inc.

May 2, 2026
Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Solid Biosciences Inc.

May 1, 2026
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Inc.

May 1, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc.

April 30, 2026